| Filed On | Filing |
|---|---|
| 05 Nov 2026 | FORM 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
CLEARWATER, FL — November 5, 2026 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported fina... |
| 28 Oct 2026 | SCHEDULE 13G |
| 29 Sep 2026 |
8-K: Other Events
Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance |
| 07 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purposes of the Apyx Medical Corporation 2026 Share Incentive Plan (the “Plan”) are to: (i) aid in maintaining and developing key employees capable of assuring the future success of Apyx Medical Corporation (the “Company”), and to of... |
| 06 Aug 2026 | FORM 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
CLEARWATER, FL — August 6, 2026 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financ... |
| 24 Jul 2026 |
8-K: Other Events
On July 24, 2026, the Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) reconstituted the membership and chairs of its standing committees as described below. |
| 21 Jul 2026 | SCHEDULE 13G/A |
| 02 Jul 2026 |
Form 4: Waldman Lawrence, Director
Received 12,000 shares by exercise or conversion ($22.6K) · Gave up 5,024 shares to cover exercise price or tax ($22.6K) |
| 26 Jun 2026 |
Proxy statement: annual meeting on August 6, 2026
CEO pay $1.2M, up 26% · say-on-pay vote |
| 17 Jun 2026 |
Form 4: Roman Shawn David, Chief Operating Officer
Received 15,000 shares by exercise or conversion ($48.5K) · Gave up 10,533 shares to cover exercise price or tax ($48.5K) |
| 17 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
This letter agreement (this “Agreement”) confirms the terms of your appointment as Executive Chairman of Apyx Medical Corporation, a Delaware corporation (the “Company”), and the grant to you of restricted stock units (“RSUs”), under the... |
| 15 Jun 2026 |
Form 4: Levine Wendy Lauren, Director
Granted 50,000 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Vizirgianakis Stavros G., Director
Received 450,000 shares as a grant or award |
| 15 Jun 2026 |
Form 4: Goodwin Charles D. Ii, Director
Granted 213,948 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Roman Shawn David, Chief Operating Officer
Granted 88,044 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Baylor-Henry Minnie, Director
Granted 50,000 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Waldman Lawrence, Director
Granted 50,000 Stock Option (Option to Buy) |
| 15 Jun 2026 |
Form 4: Hill Matthew C, Chief Financial Officer
Granted 132,066 Stock Option (Option to Buy) |
Loading...